STAMPEDE delivers yet again!

Some huge data coming out of #ESMO21 this week! And as ever, the amazing STAMPEDE trial delivers another practice-changing headline grabber. This time it's a focus on so-called "M0 high-risk" patients in STAMPEDE, with clear data showing that the addition of two years of abiratrone acetate to standard of care provides a massive benefit in metastasis-free survival and overall survival. We are joined today by STAMPEDE co-PI Professor Noel Clarke, Urologist and Professor of Urological Oncology ...